RefleXion Medical, a Hayward, CA-based medical equipment company developing biology-guided radiotherapy system for targeted, personalized cancer treatment, raised a further $6m Series B round of funding.
Johnson & Johnson Innovation made the investment which brought the total amount raised in the Series B round to $52m. The financing was led by KCK Group and joined by Venrock, Pfizer Venture Investments and Sofinnova Partners, RefleXion’s majority shareholder. In conjunction with this new funding, JJDC will obtain Board Observer status at RefleXion and will also nominate a representative from Johnson & Johnson Innovation to join the company’s Scientific Advisory Board.
Led by Dr. Samuel Mazin, Co-Founder and President, RefleXion Medical is a medical device company developing a biology-guided radiotherapy (BgRT) system for cancer treatment. By leveraging Positron Emission Tomography (PET), the company’s patented technology will allow tumors to continuously signal their location during treatment with the potential to enable focal treatment for multiple lesions throughout the body, addressing a large need amongst metastatic cancer patients, and new applications in precision medicine, where radiation delivery is adapted using novel PET radiotracers that can probe relevant tumor characteristics such as tumor hypoxia, cellular proliferation, DNA synthesis and genetic markers.